
## Kaidre Bendjama

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8227660/publications.pdf Version: 2024-02-01



KAIDDE RENDIAMA

#	Article	IF	CITATIONS
1	Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer. , 2022, 10, e003821.		12
2	Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. Cancer Immunology Research, 2022, 10, 745-756.	1.6	22
3	BERTMHC: improved MHC–peptide class II interaction prediction with transformer and multiple instance learning. Bioinformatics, 2021, 37, 4172-4179.	1.8	28
4	Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Human Vaccines and Immunotherapeutics, 2020, 16, 388-399.	1.4	56
5	Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model. Human Vaccines and Immunotherapeutics, 2018, 14, 140-145.	1.4	25
6	Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer. Human Vaccines and Immunotherapeutics, 2017, 13, 1997-2003.	1.4	8
7	Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC. , 2017, 5, 70.		45
8	Roflumilast-induced Local Vascular Injury Is Associated with a Coordinated Proteome and Microparticle Change in the Systemic Circulation in Pigs. Toxicologic Pathology, 2015, 43, 569-580.	0.9	3
9	Translation Strategy for the Qualification of Drug-induced Vascular Injury Biomarkers. Toxicologic Pathology, 2014, 42, 658-671.	0.9	13
10	A generic operational strategy to qualify translational safety biomarkers. Drug Discovery Today, 2011, 16, 600-608.	3.2	66